Sensorion announces changes in its management

Sensorion, a clinical biotechnology company, has announced the departure of its CEO, Nawal Ouzren, for personal reasons. She is being replaced by Amit Munshi, Chairman of the Board, who will serve as interim CEO. Ouzren will continue temporarily as a consultant to facilitate the transition.

During his tenure, Ouzren helped strengthen Sensorion's position in the development of hearing therapies, notably through a recent €60 million funding round led by Sanofi. This funding aims to advance Sensorion's gene therapy pipeline.

Amit Munshi expressed his gratitude to Ouzren for his leadership and pledged to continue pursuing the company's growth objectives. Sensorion is preparing for upcoming clinical milestones for its priority programs, including SENS-601 and SENS-501.